MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dysport"

  • 2026 International Congress

    Rhythmic circular stump movements after traumatic amputation: jumping stump syndrome with rapid remission after botulinum toxin type A

    P. Muangsiri, P. Chairangsaris (Bangkok, Thailand)

    Objective: To describe the clinical phenomenology and treatment response of post-traumatic jumping stump syndrome following above-knee amputation. Background: Peripherally induced movement disorders are an underrecognized…
  • 2022 International Congress

    The effects of converting to Dysport from other botulinum toxin type A formulations for treating cervical dystonia patients

    O. Samotus, M. Jog (London, Canada)

    Objective: To investigate whether Dysport increases waning time compared to other botulinum toxin type A (BoNT-A) formulations for cervical dystonia (CD) therapy. Background: BoNT-A injections…
  • MDS Virtual Congress 2020

    Cost-Analysis of the Use of IncobotulinumtoxinA and AbobotulinumtoxinA for the Treatment of Post-Stroke Upper Limb Spasticity Based on Recommended Dosing for Muscles and Clinical Patterns

    M.E Gendron, D. Vézina (Burlington, ON, Canada)

    Objective: To carry out a cost-analysis based on the respective recommended dosing per muscle using IncobotulinumtoxinA (INCO) and AbobotulinumtoxinA (ABO) for the treatment of post-stroke…
  • 2019 International Congress

    AbobotulinumtoxinA Using 2 mL Dilution Maintains Durable Functional Improvements Across Multiple Treatment Cycles

    K. Dashtipour, J. Otto, P. Maisonobe, L. Bahroo, D. Truong, R. Trosch (Loma Linda, CA, USA)

    Objective: This open-label extension (OLE) study evaluated the long-term safety and efficacy of repeat treatment cycles of abobotulinumtoxinA using 2 mL dilution (NCT01753336). Background: Cervical…
  • 2019 International Congress

    Efficacy and Safety of AbobotulinumtoxinA in Adults with Cervical Dystonia: Similar Results Between 1mL and 2mL Dilution Methods

    K. Dashtipour, R. Hauser, S. Isaacson, D. Truong, L. Bahroo, A. Patel, P. Maisonobe, J. Otto (Loma Linda, CA, USA)

    Objective: To evaluate efficacy and safety of a single injection of abobotulinumtoxinA using 1-mL or 2-mL dilution in adults with CD. Background: AbobotulinumtoxinA is approved…
  • 2019 International Congress

    Sustained Functional Benefits After a Single Injection with AbobotulinumtoxinA Using a 2mL Injection Volume in Adults with Cervical Dystonia

    A. Patel, M. Lew, A. Brashear, K. Dashtipour, S. Isaacson, R. Hauser, W. Ondo, P. Maisonobe, J. Otto (Overland Park, KS, USA)

    Objective: We present efficacy, patient-reported outcomes (PROs), and safety in adults with cervical dystonia (CD) at last available visit after a single abobotulinumtoxinA injection using…
  • 2018 International Congress

    A German-Austrian multicenter, non-interventional, prospective study for the treatment with abobotulinumtoxinA injections in naïve and previously treated patients suffering from cervical dystonia

    W. Jost, A. Schramm, M. Müngersdorf, A. Stenner, P. Schwingenschuh, P. Maisonobe, M. Koch, B. Haslinger (Wolfach, Germany)

    Objective: In this prospective, multicenter, non-interventional study (NCT01840462) the primary objective was effectiveness of abobotulinumtoxinA in BoNT treatment-naïve and previously treated subjects after two injection…
  • 2017 International Congress

    Oromandibular dystonia (OMD): A Prospective, Single-Blind Trial of AbobotulinumtoxinA (AboA)

    S. Factor, M. Silver, J. Hanfelt, E. Sperine, L. Scorr, A. Freeman, H. Jinnah (Atlanta, GA, USA)

    Objective: To examine the safety and efficacy of AboA in OMD Background: OMD causes involuntary movements of the lower facial, masticatory, and lingual muscles.  The…
  • 2017 International Congress

    Saliva changes and the oral health in Parkinson´s disease

    J. Tiigimäe-Saar, T. Tamme, P. Taba (Tartu, Estonia)

    Objective: The aim of this study was to determine the risk of change in the oral microflora and oral health in PD patients. Background: Parkinson…
  • 2017 International Congress

    Effect of early AbobotulinumtoxinA (Dysport®) use after stroke on the time to reach reinjection criteria: asymptomatic versus symptomatic patients

    R. Rosales, K.J. Goh, W. Kumthornthip, M. Mazlan, L. Abdul Latif, M.M. DeLos Santos, C. Chotiyarnwong, P. Tanvijit, J. Balcaitiene, P. Maisonobe, K.-H. Kong (Manila, Philippines)

    Objective: To determine if early post-stroke (within 12 weeks) abobotulinumtoxinA (aboBoNT-A;Dysport®) injections delay appearance or progression of upper limb symptomatic spasticity. Background: Muscle tone changes…
  • 1
  • 2
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley